Drug Profile

AB 103

Alternative Names: AB-103 - Safety Shot

Latest Information Update: 27 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Applied Biology
Developer Safety Shot
Class Skin disorder therapies; Small molecules
Mechanism of Action Minoxidil-sulfotransferase-stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase III Alopecia

Most Recent Events

01 Apr 2019 Phase-III clinical trials in Alopecia (Adjuvant therapy) in USA, in Q2 2019 (Topical) (Applied Biology pipeline, October 2021)
01 Apr 2019 Phase-III clinical trials in Alopecia in USA, in Q2 2019 (Topical) (Applied Biology pipeline, October 2021)
20 Feb 2019 Applied Biology plans a phase III trial for Alopecia (Adjuvant therapy) in Q2 2019 (Applied Biology pipeline, February 2019)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com